Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
This study has been terminated.
Sponsors and Collaborators: Baylor College of Medicine
The Methodist Hospital System
Texas Children's Hospital
Center for Cell and Gene Therapy
Information provided by: Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00040469
  Purpose

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.


Condition Intervention Phase
Sickle Cell Anemia
Hemoglobinopathy
Thalassemia
Drug: Campath -1H
Drug: Dilantin
Drug: Busulfan
Drug: Cyclophosphamide
Phase II

Genetics Home Reference related topics: beta thalassemia sickle cell disease
MedlinePlus related topics: Anemia Bone Marrow Transplantation Sickle Cell Anemia Thalassemia
Drug Information available for: Cyclophosphamide Alemtuzumab Campath Busulfan Phenytoin Phenytoin sodium
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia

Further study details as provided by Baylor College of Medicine:

Estimated Enrollment: 15
Study Start Date: August 2000
Detailed Description:

To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe thalassemia or sickle cell disease.

We will do this by using three drugs: busulfan, cyclophosphamide, and CAMPATH-1H. CAMPATH-IH is an investigational drug. CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body. After the drug treatment, participants will be given bone marrow from a brother or sister who has healthy bone marrow that matches.

  Eligibility

Ages Eligible for Study:   up to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion:

  • Patients with homozygous B0/+ thalassemia or severe variants of B0/+ thalassemia with an HLA genotypically identical donor.
  • Patients with an HLA genotype identical donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb 0/+ and at least one of the following:

Previous central nervous system vaso-occlusive episode with or without residual neurologic findings; Frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy; Recurrent SCD chest syndrome events which necessitate chronic transfusion therapy.

  • Severe anemia which prevents acceptable quality of life and necessitates chronic transfusion therapy.
  • The patient must have an HLA genotype identical donor.
  • Between the ages of birth and 65 years.
  • Women of childbearing potential must have a negative pregnancy test.

Exclusion:

  • Biopsy proven chronic active hepatitis or fibrosis with portal bridging.
  • SCD chronic lung disease >/= stage 3.
  • Severe renal dysfunction defined as creatinine clearance <40 ml/min/1.73 M2
  • Severe cardiac dysfunction defined as shortening fraction <25%.
  • HIV infection.
  • Severe but unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate bone marrow transplant (BMT).
  • Inadequate intellectual capacity to understand the nature and risk inherent in the BMT process and give informed consent (in the case of minors, this criteria must be fulfilled by the legal guardian).
  • Pregnant, lactating or unwilling to use appropriate birth control.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00040469

Locations
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
The Methodist Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
The Methodist Hospital System
Texas Children's Hospital
Center for Cell and Gene Therapy
Investigators
Study Chair: Malcolm K. Brenner, MD Baylor College of Medicine
  More Information

Study ID Numbers: H6847, Scallo2
Study First Received: June 26, 2002
Last Updated: April 9, 2007
ClinicalTrials.gov Identifier: NCT00040469  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Hemoglobin SC disease
Hematologic Diseases
Hemoglobin SC Disease
Anemia
Anemia, Hemolytic
Cyclophosphamide
Thalassemia
Sickle cell anemia
Phenytoin
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Busulfan
Alemtuzumab
Hemoglobinopathies
Hemoglobinopathy
Anemia, Sickle Cell

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Antineoplastic Agents
Therapeutic Uses
Physiological Effects of Drugs
Myeloablative Agonists
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Alkylating Agents
Immunosuppressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009